公司資料
Cogent Biosciences 股價、新聞與催化劑
- 股票代碼:
- COGT
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
37.87 USD (-0.16%)
收盤價
最後更新: 2026年8月17日
5.6B USD
市值
股價為何變動
As of Aug 17, 2026, COGT was little changed and closed at $37.87. No new same-company headline was identified in the current news window.
公司概覽
Genetically Defined Diseases
Cogent Biosciences develops precision therapies for diseases driven by defined oncogenic mutations. Its portfolio is led by a selective KIT inhibitor and includes earlier programs directed at ErbB2, PI3Kα, KRAS and JAK2.
Bezuclastinib
Bezuclastinib is designed to inhibit KIT D816V and other exon 17 KIT mutations while limiting off-target activity. These mutations drive systemic mastocytosis and are also important resistance mechanisms in gastrointestinal stromal tumors.
Systemic Mastocytosis Franchise
The company is pursuing bezuclastinib in both non-advanced and advanced systemic mastocytosis. An NDA for non-advanced disease is under FDA review, while the APEX program supports a separate planned application in advanced disease.
Gastrointestinal Stromal Tumors
The Phase 3 PEAK trial supports an NDA for bezuclastinib in GIST after prior imatinib treatment. Cogent also plans to study bezuclastinib with sunitinib in first-line exon 9-mutant GIST, potentially extending use into an earlier treatment setting.
Early Precision-Oncology Pipeline
CGT4255 is a brain-penetrant ErbB2 inhibitor and CGT6297 is a selective PI3Kα inhibitor, both in Phase 1 studies. Preclinical candidates CGT1815 and CGT1145 target pan-KRAS(ON) and JAK2 V617F, respectively.
未來催化劑
- FDA action on the bezuclastinib NDA for gastrointestinal stromal tumors by the November 30, 2026 PDUFA date.
- FDA action on the bezuclastinib NDA for non-advanced systemic mastocytosis by the December 30, 2026 PDUFA date.
- Preliminary results from the SUMMIT avapritinib-switch extension trial by year-end 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。